home / stock / ntra / ntra quote
Last: | $110.70 |
---|---|
Change Percent: | 0.59% |
Open: | $107.17 |
Close: | $110.70 |
High: | $111.79 |
Low: | $107 |
Volume: | 1,057,391 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$110.7 | $107.17 | $110.7 | $111.79 | $107 | 1,057,391 | 07-02-2024 |
$107.81 | $108.52 | $107.81 | $109.83 | $106.6 | 903,082 | 07-01-2024 |
$108.29 | $110.17 | $108.29 | $110.65 | $107.46 | 1,678,509 | 06-28-2024 |
$110.01 | $111.01 | $110.01 | $112.36 | $109.55 | 949,546 | 06-27-2024 |
$111.39 | $111.35 | $111.39 | $112.44 | $110.32 | 847,948 | 06-26-2024 |
$111.35 | $107.43 | $111.35 | $111.845 | $107.43 | 1,226,145 | 06-25-2024 |
$107.41 | $107.28 | $107.41 | $111.13 | $107.1 | 1,503,450 | 06-24-2024 |
$107.11 | $107.23 | $107.11 | $109.08 | $106.05 | 2,518,183 | 06-21-2024 |
$107.2 | $107.99 | $107.2 | $109.05 | $107.025 | 936,325 | 06-20-2024 |
$107.99 | $111.285 | $107.99 | $111.87 | $107.85 | 847,347 | 06-19-2024 |
$107.99 | $111.285 | $107.99 | $111.87 | $107.85 | 847,347 | 06-18-2024 |
$110.42 | $110.38 | $110.42 | $113.07 | $110.015 | 792,146 | 06-17-2024 |
$110.2 | $109.68 | $110.2 | $110.9 | $108.62 | 806,190 | 06-14-2024 |
$110.79 | $112.27 | $110.79 | $112.66 | $110.21 | 646,416 | 06-13-2024 |
$112.6 | $113.92 | $112.6 | $117.23 | $111.54 | 1,041,253 | 06-12-2024 |
$112.47 | $111.4 | $112.47 | $112.585 | $108.9225 | 824,716 | 06-11-2024 |
$111.66 | $110.23 | $111.66 | $112.72 | $109.5 | 1,370,538 | 06-10-2024 |
$111.19 | $109.15 | $111.19 | $111.6 | $107.17 | 906,775 | 06-07-2024 |
$109.22 | $110.83 | $109.22 | $111.395 | $108.87 | 691,903 | 06-06-2024 |
$110.79 | $106.97 | $110.79 | $112.05 | $106.23 | 1,069,440 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that its latest research and data on prenatal and reproductive genetics will be presented at the 28th International Conference on Prenatal Diagnosis and Therapy. Hosted by the Internationa...
First-of-its-kind study in gastroesophageal adenocarcinoma using Signatera to guide treatment and assess the efficacy of a novel HER2-directed adjuvant treatment Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new gastroes...
2024-06-23 13:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...